
==== Front
Cancer Control
Cancer Control
spccx
CCX
Cancer Control : Journal of the Moffitt Cancer Center
1073-2748
1526-2359
SAGE Publications Sage CA: Los Angeles, CA

39215442
10.1177_10732748241274196
10.1177/10732748241274196
Review Article
The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance
https://orcid.org/0009-0007-6692-2648
Zhong Chen 1
Wang Guojuan MD 2
Guo Min 1
Zhu Naicheng 1
Chen Xiudan 1
https://orcid.org/0009-0005-6418-0412
Yan Yuwei 1
https://orcid.org/0009-0006-4412-0997
Li Nanxin 1
Yu Wenyan MD 1
1 74582 Jiangxi University of Chinese Medicine , Nanchang, China
2 Affiliated Hospital of Jiangxi University of Chinese Medicine , Nanchang, China
Wenyan Yu, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China. Email: wenyan.yu@jxutcm.edu.cn
30 8 2024
Jan-Dec 2024
31 1073274824127419624 2 2024
9 7 2024
23 7 2024
© The Author(s) 2024
2024
SAGE Publications Inc, unless otherwise noted. Manuscript content on this site is licensed under Creative Common Licences
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Background: Colorectal cancer is a major cause of mortality among the prevalent malignant tumors of the gastrointestinal tract. Although chemotherapy is a standard treatment for colorectal cancer, its efficacy is limited by chemoresistance. Recent studies have investigated targeting tumor stem cells as a potential new therapeutic approach for addressing chemoresistance in colorectal cancer. Colorectal cancer frequently relapses, with tumor stem cells often representing one of the leading causes of treatment failure. Purpose: Understanding drug resistance in colorectal cancer stem cells is crucial for improving treatment outcomes. By focusing on developing targeted therapies that specifically address drug resistance in colorectal cancer stem cells, there is potential to make significant advancements in the treatment of colorectal cancer.This approach may lead to more effective and lasting outcomes in patients battling colorectal cancer. Research Design: In this review, a comprehensive overview of recent research on colorectal cancer stem cell treatment resistance is presented.Results: Elucidating the key underlying mechanisms. This review also highlights the potential benefits of targeted therapies in overcoming colorectal cancer resistance to treatment. Conclusions: CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.The significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs is been highlighted.

cancer stem cells
colorectal cancer
drug resistance
chemotherapy
Jiangxi University of Traditional Chinese Medicine School-level Science and Technology Innovation Team Development Program Project No.CXTD22011 Jiangxi Provincial Traditional Chinese Medicine Youth Key Talents (the Fourth Tranche) Training Program Gan Traditional Chinese Medicine Science and Education 2022 No.7 National Natural Science Foundation of China https://doi.org/10.13039/501100001809 82160925 82205221 Natural Science Foundation of Jiangxi Province https://doi.org/10.13039/501100004479 20224BAB206097 typesetterts10
cover-dateJanuary-December 2024
==== Body
pmcIntroduction

Colorectal cancer (CRC) is a complex disease that ranks second in mortality and third in morbidity rates among common malignancies. It is estimated that over 1.9 million new cases occurred in 2020.1,2 A range of risk factors, including physical activity, dietary habits, genetics, and others such as smoking, alcohol consumption, and caffeine intake, may contribute to the development of CRC. The oncogenic factors prompt the epithelial cells of colorectal mucosa to undergo a sequence of transformations, culminating in the development of CRC. This progression involves hyperplasia, dysplasia, adenomas, and ultimately carcinoma.3,4 While surgery and chemotherapy remain the primary treatment modalities for CRC, the prognosis for advanced stages remains unsatisfactory, highlighting the need for more effective therapeutic strategies. By contrast, early-stage CRC often has a more favorable prognosis. Despite the promising initial therapeutic effect of neoadjuvant therapy in advanced CRC patients, the relapse rate remains high, primarily due to drug resistance developed by tumor cells during treatment. 5 Therefore, there is an urgent need to delve into the mechanisms underlying drug resistance in CRC to enhance treatment efficacy and improve patient outcomes.

Cancer drug resistance ensues from cancer cells' continuous adaptation within the tumor microenvironment (TME), giving rise to diverse inhibitory networks and mechanisms that undermine the effectiveness of antitumor therapy. 6 Cell resistance in cancer encompasses tumor heterogeneity, oncogenic mutations, epigenetic modifications, plasticity of cancer stem cells, and tumor-host interactions. 7 After antitumor therapy, residual cancer cells may remain dormant and then reactivate due to adaptive responses, leading to cancer recurrence. 8 Drug resistance in CRC is a complex phenomenon involving altered metabolism, target modifications, aberrant activation of resistance-related signaling pathways, and changes in TME.9-11 Abnormal expression of drug resistance-linked microRNAs (miRNAs) disrupts hormonal signaling, leading to therapeutic resistance. These miRNAs can be targeted to develop anticancer drugs that overcome resistance in cancer progression. 12

Stem cells, characterized by their long-term self-renewal and differentiation capabilities triggered by soluble factors, play a pivotal role in organ and tissue proliferation and regeneration.13-15 Cancer stem cells (CSCs), a subpopulation within tumors, possess these same stem cell traits, but with the addition of resistance to radiotherapy and chemotherapy. 16 Furthermore, a subset of CSCs with metastatic potential develops resistance to anticancer drugs, posing a significant challenge in cancer treatment. 17 Chemotherapy often leaves residual CSCs in tumors, 18 causing rapid tumor regrowth once treatment stops. CSCs rapidly reconstitute the original tumor mass in the absence of drug-induced damage particularly in colon cancer. By conducting serial transplantation in mice, residual CRCs were enriched for colorectal cancer stem cells (CCSCs) with increased ALDH1 activity, potentially conferring resistance to cyclophosphamide. Colon cancer cells produce IL-4, upregulating anti-apoptotic genes and promoting cancer cell survival. These findings suggest a role for ALDH1 and IL-4 in CRC stem cell phenotype and resistance development. IL-4 functions to safeguard colon CSCs and promote their resistance to cell death. The subset of CSCs that manage to survive chemotherapy plays a pivotal role in the recurrence of tumors.19-21 Moreover, the administration of cisplatin (CDDP) contributes to the enrichment of CSCs, potentially through upregulation of the TRIB oncogene and histone deacetylase class I (HDAC) activity, or activation of the NF-κB/TNFα/PIK3CA signaling pathway. 22 The process of chemotherapy and subsequent acquisition of drug resistance are implicated in the proliferation of CSCs. The potential of targeted therapy lies in its ability to effectively eliminate both progenitor cells and CSCs, thereby enhancing clinical outcomes for cancer patients. 23 In CRC, understanding the mechanisms of drug resistance, especially as it pertains to CSCs, is crucial in identifying promising therapeutic targets and ultimately enhancing treatment efficacy.

Mechanisms of Drug Resistance in Colorectal Cancer

Cancer chemotherapy often fails due to drug resistance, a significant obstacle in treatment. Multidrug resistance (MDR) particularly poses a challenge, arising from tumors’ capacity to develop resistance to multiple drugs with diverse origins, structures, and mechanisms. MDR can be either intrinsic or acquired, both contributing to the failure of cancer treatment. The natural resistance of cancer cells to treatment is known as intrinsic drug resistance, whereas acquired drug resistance arises when treated cells gradually become insensitive to drugs.24,25 Resistance in CRC can be attributed to changes in drug efflux, targeting, disrupted apoptotic pathways, TME, CSCs, and signaling pathways.9,26 The main mechanisms of CRC drug resistance are described below (Figure 1).Figure 1. Mechanisms of drug resistance in colorectal cancer. (A) Increased drug efflux. (B) Drug target changes. (C) Apoptosis. A: Antiapoptotic protein. p: proapoptotic protein. (D) LncRNAs can promote CRC drug resistance by regulating certain miRNAs. (E) Extracellular vesicles. (F) Tumor stem cell. sp: signaling pathway.

Induction of Drug Transporter Protein Expression

The absorption, distribution, and efflux of various drugs are modulated by drug transporter proteins, significantly influencing drug efficacy. Notably, drug efflux, enabled by these proteins, promotes the expulsion of substrates and therapeutic drugs from cells, leading to diminished concentrations of antitumor agents within cancer cells and the subsequent emergence of drug resistance.27,28 Transporter proteins, categorized into solute carrier protein (SLC) and ABC types, are key players in drug efflux, with the latter group playing a dominant role. 29 These ABC transporter proteins, including P-glycoprotein (P-gp), multidrug resistance protein (MRP1), and breast cancer resistance protein (BRCP), 30 contribute significantly to drug resistance in colon cancer cells. This resistance is enhanced by the expression of these proteins, which is induced by the IRE1α-XBP1 axis. The upregulation of these transporter proteins by anti-cancer drugs can lead to reduced drug efficacy and increased cancer cell survival. 31

Changes of Drug Targets

Targeted drugs aim to minimize toxicity and side effects in the treatment of CRC. They typically target DNA, cell surface receptors, and other intracellular structures. Modifications to these sites can disrupt the drug’s normal pathway, contributing to drug resistance in CRC.

High expression of thymidylate synthase

DNA replication relies on thymidylate synthase (TS), which catalyzes the conversion of dUMP to dTMP, essential for thymine biosynthesis. 32 As thymine is a fundamental component of nucleic acids and DNA, TS inhibition represents a promising approach for anticancer drug design, particularly given the elevated DNA synthesis activity observed in cancerous cells. The primary mode of action of 5-fluorouracil (5-FU) as an anticancer agent involves the inhibition of TS. A distinctive form of drug resistance associated with 5-FU is characterized by elevated levels of TS expression. 33 TS binds to its mRNA, maintaining a negative feedback loop that suppresses protein translation. 5-FU metabolism generates fluoro deoxyuridine monophosphate (5-FdU), which stably binds to TS, preventing its mRNA interaction. This disrupts the feedback loop, elevating TS protein levels. In vitro studies reveal that a rapid TS surge enhances resistance to 5-FU. 34

Low expression of DNA topoisomerase 1

DNA topoisomerases (DNA TOPOs) alleviate the torsional strain by temporarily cleaving and resealing DNA strands, enabling the resolution of topological challenges associated with the extended nature of human double-helical DNA polymers.35,36 The antitumor activity of irinotecan is enabled by its conversion into SN-38 by carboxylesterase (CES), which inhibits Topoisomerase 1 (TOPO-1), a type I topoisomerase that cleaves only one DNA strand. Furthermore, the resistance of irinotecan against CRC may be associated with the low expression of TOPO-1.37,38

Mutations of epidermal growth factor receptor structure

Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase (RTK) protein family, sharing a conserved architecture comprising an extracellular structural domain (ECD), a transmembrane structural domain (TMD), a juxtamembrane domain (JMD), a tyrosine kinase domain, and a C-terminal tail. Signal transduction is mediated by diverse ligands, including high-affinity ligands such as EGF, transforming growth factor alpha (TGF-α), and heparin-binding EGF-like growth factor (HB-EGF). 39 Therapeutically, monoclonal antibodies like panitumumab and cetuximab target the EGFR by binding to its ECD, thereby preventing ligand binding and exerting a therapeutic effect. 40 However, ECD mutations can impact cetuximab’s binding, leading to resistance against this EGFR monoclonal antibody.41,42

Alteration of Microtubule Structure

Microtubules, dynamic cytoskeletal fibers made up of tubulin subunits, play a key role in mitotic spindle microtubule formation, making them a prime target for anticancer therapy. Current microtubule-targeting agents, such as paclitaxel and Vinca alkaloids, function by inhibiting microtubule dynamics. Mutations in microtubule structure, altered tubulin expression, and regulation of microtubule-associated proteins can all influence microtubule dynamics. Furthermore, structural changes can affect drug binding, dynamics, and structure, potentially explaining drug resistance mechanisms.43,44

Imbalance of Apoptosis-Regulating Proteins

Apoptosis, the programmed death of cells that eliminate harmful or damaged ones, 45 is the desired endpoint of cytotoxic chemotherapy. Central to apoptosis regulation is the BCL-2 family, whose proteins maintain a delicate balance. Disturbances in this equilibrium, often caused by overexpression of BCL-2 and its homologs, can lead to drug resistance. To improve patient prognosis, new therapies aim to normalize cellular pathways while mitigating mitochondrial activation, thereby restoring apoptotic function. 46

Dysregulation or Mutation of the Signaling Pathways

Cellular signaling, a crucial process that triggers responses between cells, involves various signaling pathways such as Wnt/β-catenin, PI3K/AKT/mTORC1, and JAK/STAT. These pathways play a regulatory role in CRC development.47-49 However, dysregulation or mutations in these pathways can lead to further alterations in other cellular processes, ultimately resulting in drug resistance. CRC progression is typically associated with mutations in the Wnt/β-catenin pathway, regulating tumor stemness and metabolism, thus affecting chemoresistance. 50 Aberrant Wnt signaling plays a significant role in cancer chemoresistance. This resistance arises from various mechanisms such as ligand upregulation of the Wnt pathway, miRNA level changes, transporter gene expression, and β-catenin gene mutations.51,52 Progress in drug resistance often involves Wnt7b modulating the upregulation of multidrug resistance genes like ABCB1 and ABCG2, facilitating drug efflux. Targeting these mechanisms offers potential therapeutic avenues to overcome cancer chemoresistance. 53

Other Resistance Mechanisms

While miRNAs, non-coding RNAs (ncRNAs), regulate crucial cellular processes such as angiogenesis, signaling pathways, and epithelial-mesenchymal transition (EMT) linked to CRC, several miRNAs are emerging as promising therapeutic targets for combating colon cancer, influencing cell proliferation, metastasis, and chemoresistance. 54 LINC00473, a cancer-related Long-strand non-coding RNAs (LncRNAs), enhances CRC drug resistance by suppressing miR-15a, a tumor suppressor miRNA. This downregulation of miR-15a leads to activation of the BCL-2-associated anti-apoptotic pathway, enhancing paclitaxel resistance and inhibiting tumor regression. 55

Extracellular vesicles (EVs) are diverse membranous structures that are secreted by cells. 56 EVs play a significant role in promoting cancer invasion and progression in CRC. These vesicles remodel TME by secreting cytokines, chemokines, and ncRNAs, which enhance tumor growth and drug resistance. EVs also induce apoptosis in cytotoxic T cells (CD8+), further facilitating tumor evasion from immune surveillance. Understanding the role of EVs in CRC progression holds promise for developing novel therapeutic strategies.57,58

CSCs play a crucial role in CRC drug resistance due to their self-renewing abilities. Multiple mechanisms linked to CSC phenotypes could underlie CRC drug resistance.59,60 Understanding CSCs in CRC holds promise for discovering novel therapeutic approaches to treating tumors and their metastases.

Mechanisms of Tumor Stem Cell Drug Resistance

Concept and Origin of Tumor Stem Cells

CSCs exhibit a high level of proliferation and lack of differentiation, originating from genetic mutations or disrupted genetic processes in regular stem or progenitor cells. These cells possess distinct characteristics including markers of stemness, proteins associated with metastasis, drug transporters, and heightened expression of DNA repair mechanisms, which contribute to their involvement in tumor initiation, advancement, invasion, relapse, and resistance to treatment.61-63 Furthermore, the invasive and metastatic capabilities of CSCs may be acquired through the activation of the EMT process. 64 The dynamic transition between stem and non-stem-cell states in certain cancer cells plays a crucial role in influencing the effectiveness of treatments. These cells, often inaccurately labeled as CSCs, possess the ability to switch between states reversibly. This plasticity in stemness is a fundamental factor that impacts therapeutic outcomes. 65 Additionally, the process of chemotherapy-induced cellular senescence, along with the influence of nitric oxide and other soluble signaling factors in TME, further enhances the acquisition of stemness in cancer cells.66,67 CSC was initially introduced by Makino 68 and colleagues in 1956, suggesting that all cancer cells are derived from self-renewing CSCs. This hypothesis offers a plausible explanation for the resistance to treatment and quiescent nature observed in various tumors.69,70 John E. Dick’s research team was the first to identify and characterize CSCs in myeloid leukemia,71,72 demonstrating their ability for self-renewal and differentiation. After years of similar experiments, researchers confirmed the existence of CSCs in CRC and other solid tumors.73,74 Their pivotal role in chemoresistance underscores the urgency of exploring alternative treatment options. Recently, the advancement of CSC models has garnered increasing attention. During the transition from normal colonic epithelial cells to cancer cells, stem cell characterization is crucial. By exploring the similarities and differences between normal stem cells and CSCs, reliable stem cell models can be developed. These models offer a platform for Mechanism-based research and innovative drug discovery, to overcome drug resistance challenges. The development of drug-resistant stem cell models for colon cancer is a crucial area of research, with sulindac (SUL) and 5-FU being commonly used inducers. These models assess the acquisition of stem cell properties by measuring the expression levels of key molecules and markers like CD44, CD133, and ALDH1.75,76

Mechanisms of Tumor Stem Cell Resistance

CSCs possess the ability to trigger cancer development during tumor cell resistance and replenish cancer cells under specific conditions, making them resistant to treatment and contributing to tumor recurrence.77,78 This resistance is linked to quiescence, exaggerated DNA repair mechanisms, suppression of apoptosis, the acquisition of an EMT phenotype, the elimination of reactive oxygen species (ROS), and the upregulation of aldehyde dehydrogenase (ALDH) activity79-83 (Figure 2).Figure 2. Mechanisms of drug resistance in tumor stem cells. (A) Three ecological niches of CSCs in a quiescent state. (B) DNA repair mechanisms: H: homologous reorganization N: non-homologous end joining B: base excision repair R: Reduced programmed cell death activity. (C) EMT phenotype. (D) Scavenging of ROS. (E) Enhancement of ALDH activity. sp: signaling pathway.

The existence of Stationary States

The specialized microenvironments within tumors known as CSC ecotopes support and sustain CSCs. 84 The quiescent nature of these CSCs is closely linked to the hypoxic and perivascular niches within the TME, which foster resistance to treatment. CSCs can thrive in both niches, enabling them to persist and contribute to tumor recurrence and metastasis. The ecological niche at the invasion edge supports CSCs, although the exact role remains speculative.85,86 Under hypoxic conditions, hypoxia-inducible factor (HIF) signaling is activated in the hypoxic zone, leading to increased CSC proliferation by upregulating embryonic stem cell transcription factors such as SOX2, Oct3/4, and Nanog. 87

Overexpression of DNA-Repair Mechanisms

The genetic stability of CSCs is crucial, as DNA damage leads to mutations that affect their survival. 88 Despite this, cancer cells often show resistance to DNA damage therapy, potentially due to their enhanced DNA repair mechanisms, 89 including homologous recombination, non-homologous end joining (NHJ), base excision repair (BER), and decreased activity of programmed cell death. To overcome drug resistance in chemo or radiotherapy, inhibiting at least two DNA repair mechanisms concurrently is crucial. 79

The Acquisition of EMT Phenotypes

EMT is a process that involves the loss of apical-basal polarity and enhanced motility of epithelial cells, leading to increased cell migration and invasion capabilities. 90 EMT plays a crucial role in cancer invasion, metastatic spread, and acquisition of therapeutic resistance. Transforming growth factor-β (TGF-β) induces EMT in cancer pathogenesis by activating signaling pathways in CSCs, such as the Wnt signaling pathway. 91 EMT facilitates the emergence of drug-resistant cancer cells resembling CSCs by inducing stem cell-like properties and overexpressing ABC transporter proteins. Conversely, triggering EMT in a targeted manner can abolish CSC stemness and drug resistance. 80

Removal of ROS

ROS, a chemically reactive byproduct of oxygen metabolism, is produced primarily in mitochondria and peroxisomes. Low ROS levels sustain normal signaling functions, whereas elevated concentrations cause cellular harm.92-94 The stemness marker NANOG plays a crucial role in inhibiting oxidative phosphorylation in CSCs, leading to decreased mitochondrial ROS generation and enhanced fatty acid oxidation. This helps maintain CSC self-renewal and drug resistance. 95 Furthermore, genes involved in ROS scavenging, such as glutathione peroxidase (GPX), are upregulated in breast cancer CSCs, enhancing their resistance to radiotherapy. 96 Hence, maintaining low ROS levels is a significant mechanism underlying CSC drug resistance.

Enhancement of ALDH Activity

Aldehyde dehydrogenase (ALDHs), a type of NADP-dependent detoxifying enzymes, oxidize toxic aldehydes into carboxylic acids, vital for retinoic acid (RA) synthesis in cellular processes. 97 These enzymes play a significant role in CSCs, promoting DNA repair and reducing ROS, thereby contributing to the CSC phenotype. 98

Promotion of Tumor Stem Cells in CRC Drug Resistance

Currently, there’s evidence indicating that cancers in humans, including CRC, can be viewed as stem cell disorders. 99 CCSCs, derived from ISC and transporter-expanded cells, play a significant role in CRC heterogeneity. CCSCs are characterized by unique surface markers like CD133, which plays a vital role in primitive cell differentiation and EMT. 59 CSCs, linked to tumor angiogenesis, are key drivers of CRC growth, metastasis, drug resistance, and recurrence. 100 Hence, personalized CRC therapy should prioritize targeting these cells.

Colorectal cancer stem cells (CCSCs), similar to other tumor stem cells, exhibit aberrant proliferative signaling like Wnt, Notch, and Hedgehog, along with heightened tumorigenicity. Like intestinal stem cells, they maintain self-renewal and differentiation abilities.101,102 Prolonged drug therapy can increase CSCs by 30%, leading to treatment resistance. The dysregulation of Wnt, Notch, and TGF-β signaling pathways in intestinal epithelial cells, along with the upregulation of specific miRNAs in CCSCs, together promote stemness in these cells. 103 TME in CRC offers a protected niche for CSCs, within which matrix components secrete active factors that impact CRC cell and CSC properties via multiple pathways of action.104,105 In recent years, numerous studies have explored these signaling pathways, miRNA aberrations, and the role of the TME in CRC. This review summarizes and synthesizes these findings, aiming to provide valuable insights for the development of effective CRC treatments (Figure 3). Hope that they can help in the treatment of CRC.Figure 3. Mechanisms of cellular resistance in colorectal cancer tumor stem cells. (A) Regulation of signaling pathways represented by the Wnt/β-catenin pathway. (B) miRNA regulation. (C) Tumor microenvironment regulation. ie: expression enhancement. fe: functional enhancement. CCRC-A-M:CCRC-associated-marker.

Promoting Drug Resistance in CCSCs by Modulating Relevant Signaling Pathways

The resistance to treatment in CRC is partly attributed to aberrant signaling pathway activation in CSCs. The key pathways include Notch, Wnt/β-catenin, and Hedgehog (Hh), regulating CSC stemness. Resistance in CRC cells is linked to these signaling pathways and their cross-talk.106,107 Therefore, they also contribute to drug resistance in CCSCs.

Activation of the WNT/β-Catenin Signaling Pathway

The Wnt pathway’s aberrant activation is a pivotal driver in human cancer development, especially CRC. 108 This pathway, which regulates stem cell survival, proliferation, and self-renewal, suggests that disrupting Wnt signaling could halt CSC maintenance.109,110 Real-time visualization of stem cells reveals that more differentiated cells can replace damaged stem cells, reverting to the stem cell niche and regaining stemness, possibly mediated by activated Wnt signaling. 111 The Wnt signaling pathway plays a crucial role in stem cell formation and carcinogenesis, acting to initiate CSCs. CD44 and CD24, surface markers of cancer stem cells, are Wnt target genes. 52 CD44-positive cells exhibit translocation of β-linker proteins to the nucleus, expressing β-linker target genes, whereas CD44-negative cells lack nuclear β-linker proteins. This observation suggests that Wnt signaling may be a critical component in CSC initiation. 112 Although compelling evidence exists, further exploration of the Wnt signaling pathway’s role in CSCs’ development is essential. This pathway, both typical and atypical, plays a pivotal role in cancer’s progression. The typical Wnt pathway regulates β-catenin levels during gene expression. Anomalous activation or genetic alteration of the conventional Wnt signaling pathway results in increased β-catenin activity, promoting tumorigenesis and the sustenance of CSCs.113,114 Nevertheless, the accumulation of β-catenin in the cytoplasm in the absence of Wnt signaling is impeded by the degradation of a complex protein structure comprising adenomatous polyposis coli (APC) and other constituents of this pathway. 115 Notably, mutations in the APC gene are detected in approximately 80%-85% of sporadic CRCs, and the inactivation of this gene serves as a trigger for the onset of colorectal neoplasia. A study has discovered that CRCs exhibiting intact APC genes harbor activating mutations in β-catenin. APC plays a crucial role in maintaining low nuclear β-catenin levels through promoting its export, which disrupts the binding of β-catenin with TCF/LEF and subsequently curbs the transcription of genes implicated in CRC progression.116-118

The Wnt signaling target Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5), a CCSC marker, can be stimulated with MEK1/2 inhibitors to elevate LGR5 levels. This enhances CSC quiescence and drug toxicity evasion.119,120 Blocking the Wnt/β-catenin pathway diminishes ABC transporter mRNA expression in CRC cells, thereby reducing protein levels and heightening sensitivity to chemotherapy. 121 Increased glycolysis is observed in cancer cells that are resistant to chemotherapy. The activation of the Wnt/β-catenin signaling pathway is linked to drug resistance as it enhances glycolysis. 122 Stem cells residing in a hypoxic environment stimulate glycolysis through the activation of the Wnt/β-catenin signaling pathway, resulting in the increased expression of solute carrier family 2. 121 The Wnt signaling pathway is crucial in regulating drug resistance in CSCs. By stimulating the expression of Lgr5, ABC transporter proteins, and glycolysis, the pathway enhances CSC drug resistance. Various regulatory factors influence CCSCs via the Wnt pathway, further modulating resistance. Among these, β-catenin’s highly homologous coactivators, CBP and p300, play a significant role. While p300/β-catenin binding fosters CSC differentiation, CBP/β-catenin association preserves CSC potency.123,124 Suppressing miR-148a upregulates CCSC markers via the Wnt/β-catenin pathway, minimizing cisplatin resistance. 114 Through examination of gene expression patterns in CRC patients, it has been observed that the cluster of differentiation 45 (CD45), which is encoded by the protein tyrosine phosphatase receptor type C (PTPRC) gene, is preferentially expressed in CCSCs. The phosphatase activity of CD45 is implicated in enhancing Wnt transcriptional activity by stabilizing β-catenin, thereby promoting stemness and drug resistance characteristics. This mechanism sheds light on how cancer stem cells sustain abnormal activation of the Wnt signaling pathway and suggests a potential therapeutic approach for treating CRC. 125 Additionally, Sec62, a newly identified target associated with chemoresistance in CRC, is a protein-coding gene that also contributes to the stabilization of β-catenin and the promotion of cancer stemness through β-catenin signaling. Targeting Sec62 has the potential to enhance the effectiveness of chemotherapy in CRC patients by inhibiting β-catenin signaling. 126 Furthermore, GANT61, a selective inhibitor of Gli (a transcription factor in the Hedgehog signaling pathway closely linked to CRC pathology), has been shown to simultaneously block the Wnt/β-catenin and Notch signaling pathways in CRC, leading to the elimination of CCSCs. 127 In addition to in vivo gene expression studies, recent research has also explored the effects of bioactive compounds from exotic plants. For instance, Procyanidin has been found to down-regulate surface markers and transcriptional factors associated with stemness in cancer stem cells, as well as inhibit their proliferation through the Wnt/β-catenin pathway. 128 Without mutations, the activation of the Wnt/β-catenin pathway is precluded, affecting APC genes and other Wnt-regulating proteins. Surface markers and β-catenin, however, serve to preserve stemness in CSCs.

Bidirectional regulation of CSCs via the notch signaling pathway

When the Notch signaling pathway is disrupted, it can also foster tumor growth, alongside the Wnt pathway. Notch is involved in diverse cellular processes, promoting survival, proliferation, and suppressing apoptosis. Whether it behaves as an oncogene or tumor suppressor gene depends on the cellular microenvironment.129,130 The discovery of Notch signaling genes in the wing notch of Drosophila melanogaster in 1917 has linked them to leukemia and various cancers, such as CRC. 131 The Notch pathway is bifurcated into canonical and non-canonical subtypes. The canonical Notch pathway stimulates transcription of target genes, retards differentiation, and preserves stem cell properties. Alternatively, the non-canonical Notch pathway emerges from atypical ligands, creating the CSL-NICD-Deltex complex that triggers MAG transcription and enhances differentiation. 132

Notch signaling maintains the properties of CCSCs and inhibits apoptosis by repressing the cell cycle inhibitor p27. 133 JAG2, a significant ligand of the Notch pathway, is utilized to sustain a stem cell-like state. Depletion of JAG2 leads to the inhibition of the stem cell-like marker CD133. 134 Disruption of the PRC2 complex formation in CSCs can have a significant regulatory impact on Notch signaling. 135 Additionally, certain agents have been identified to modulate drug resistance in CSCs through the Notch pathway. Nanotechnology has been employed to transport anticancer medications, enhancing their efficacy and stability. α-Mangostin (αM) exhibits anti-proliferative and apoptotic properties in cancer cells. At low concentrations, αM hinders CCSCs and counteracts the 5-FU-induced promotion of CSCs via the Notch signaling pathway. 136 α-Mangostin nanoparticles (αM-PLGA nanoparticles) impede the self-renewal ability of CCSCs and CRC carcinogenesis through the Notch pathway. 137 Jin 135 and colleague’s study discovered that serine-threonine kinase receptor-associated protein (STRAP) epigenetically controls the Notch pathway, maintaining stem cell-like features of CRC cells by boosting HES1 and transcriptional-level stemness markers. PER3, a circadian clock gene, plays a key role in this process. When overexpressed, it downregulates stemness markers, Notch1, and β-catenin, thus promoting CCSCs’ self-renewal and chemoresistance. 138 Significantly, prolactin (PRL) has the ability to stimulate Notch signaling via the JAK2-STAT3 or JAK2-ERK1/2 pathways, thereby augmenting stem cell activity in 3 colon cancer cell lines. 139 The oncogenic histone cluster 2 H2B family member F (HIST2H2BF) plays a role in upregulating the expression of NICD, an activated form of Notch1, which in turn facilitates downstream gene transcription and the phenotype of CCSCs. 140 There is promise in the utilization of Traditional Chinese Medicine within cancer treatment settings. For instance, Evodiamine, a compound with dual-targeting capabilities against both colon cancer cells and CSC, exhibits inhibitory effects on Wnt and Notch signaling pathways in CSC. 141 These investigations underscore potential novel therapeutic targets for CRC.

Maintenance of CSCs in a Proliferative State by Hh Signaling Pathway

Cancer, particularly colon cancer, is linked to dysregulation of the Hh signaling pathway. This dysregulation arises from mutations in genes related to the pathway or increased expression of Hh molecules, with the difference requiring a ligand for signal transduction in the latter. 142 Despite the rare activation of Hedgehog signaling in CRC due to negative regulation of the Wnt pathway, Hh signaling maintains the undifferentiated, clonally proliferative state of CSCs, serving as a potential foundation for other tumor studies, including CRC.143,144 Moreover, non-classical Hedgehog signaling enhances Wnt gene expression and hinders CSC differentiation in vivo. 145 The extent or rate at which the Hh signaling pathway promotes self-renewal of CCSCs plays a key role in tumor maintenance and expansion. 146 This pathway involves 3 genes: Sonic Hedgehog (SHh), Indian Hedgehog (IHh), and Desert Hedgehog (DHh). 142 A compound known as Physciosporin has been identified as an inhibitor of BCC stemness and ALDH1 expression, which is mediated through the SHH and Notch signaling cascades. ALDH1, a distinct marker for CCSCs, promotes metastasis and proliferation of these cells via various well-established biological pathways.147,148 Gli proteins serve as downstream effectors of the classical Hh signaling pathway, facilitating the transcriptional activation of target genes within this pathway. 142 The distinctive spherical morphology of HCT-116 cells is associated with CSCs, and the administration of cyclobenzaprine, a Sonic hedgehog (Shh) inhibitor, induces or elevates the mRNA levels of CHD1 (a gene expressing E-calmodulin) within the colon cancer spheres of the HCT-116 cell line by suppressing Gli1. 149 Garcinone C has been found to impede CCSCs by interacting with Gli1 and promoting its degradation, resulting in a notable reduction of stemness markers such as CD44, CD133, ALDH1, and Nanog. 150 Conversely, the transcription factor RUNX3 diminishes the expression of Gli1-mediated stemness markers in stem-like CRC cells, thereby suppressing their stemness characteristics. 151

Other Signaling Pathways with Different Mechanisms

In CRC resistance, there exist alternative signaling paths regulating CCSCs. APC and K-Ras mutations enhance CCSC activation, promoting tumorigenesis. High RAS protein levels correlate with β-catenin expression. CDP0857 mitigates CCSC activation by modulating Wnt/β-catenin and Ras/signal-regulated kinase (ERK) signaling. 152 The Radiation-induced PI3K/AKT pathway plays a key role in SOX2-induced CCSC activation, highlighting its therapeutic potential against radiation-activated CCSCs. 153 The JAK/STAT signaling pathway plays a pivotal role in the growth of CCSCs post-radiotherapy (RT). JAK2 overexpression in CCSCs influences CRC cell radio-resistance and stemness via targeted regulation of CCND2, a crucial cell cycle protein.154,155

The signaling pathways connecting the preceding and following elements serve as bridging mediators in CCSCs' drug resistance mechanism. Targeting these pathways to affect CSC properties could provide a viable approach for treating CRC patients.

The Role of miRNAs Regulation in the Drug Resistance Process of CCSCs

MicroRNAs, short noncoding RNAs, play a crucial role in cancer pathogenesis. 156 Their expression in CSCs contributes to colorectal cancer heterogeneity and is linked to uncontrolled proliferation and metastasis. 157 CCSC-related miRNAs primarily target signaling pathways and molecules key for CCSC maintenance and oncogenic functions, often inversely correlating with cellular expression. 158 CCSCs demonstrate bidirectional miRNA expression regulation. Comprehending this phenomenon which is the underlying factors that influence tumor heterogeneity is critical for guiding targeted miRNA drug delivery, eliminating cancer stem cells, and enhancing cancer treatment efficacy, thereby supporting better cancer management. 159

miR-7-5p overexpressed directly enhances radiosensitivity by targeting KLF4, leading to compromised CCSCs characteristics. 160 By contrast, miR-320d upregulation suppresses c-Myc expression, improving CCSCs’ chemosensitivity. 161 Additionally, high Long Intergenic Non-protein Coding RNA 01315 (LINC01315) expression observed in CRC is shown to regulate CCSCs’ extracellular characteristics and EMT upon silencing. 162 MiR-148a regulates Wnt10b and β-catenin pathways at least in part, inhibiting stem cell markers and enhancing chemosensitivity, invasion, and migration. 163 The previous research led by Lucile Bansard 164 and her colleagues established that Pregnane X Receptor (PXR) expression and activity are hallmarks of recurrence-prone CCSCs. In a follow-up study, they further revealed that the expression of miR-148a-3p is reduced in colonic hematopoietic stem cells, and its up-regulation effectively suppresses PXR expression and function. The overexpression of the suppressor of cytokine signaling 3 (SOCS3) reduces the stemness of CRC cells. MiR-92a is crucial in maintaining CRC stemness by suppressing SOCS3. 165 On the other hand, miRNA-483-3p activates the ERBB3-AKT pathway by targeting NDRG1, which supports EMT and stem cell features, thereby driving the invasive growth of CRC. 166 MiR-103/107 activates Wnt/β-catenin signaling and miR-372/373 overexpression downstream, enhancing stemness and chemoresistance in CRC cells.167,168 MiR-8063 downregulation impairs its inhibitory effect on human heterogeneous ribonucleoprotein complex antibody (hnRNPAB), activating Wnt/β-catenin signaling and CCSC self-renewal. 169 MiR-451 regulates the growth of CSCs by targeting macrophage migration inhibitory factor (MIF), involved in cyclooxygenase-2 (Cox-2) and Wnt signaling. 170 Down-regulation of stem cell-associated miRNAs, such as miR-302, miR-369, and miR-200c, can alleviate MRP8 (ABCC11) inhibition, reducing sensitivity to 5-FU in CRC cells. 171 The promotion of stemness and liver metastasis in colorectal cancer by MiR-3065-3p involves the suppression of the downstream gene CRLF1 172 Additionally, the lncRNAHOX, HOTAIR, aids in the expression of the miR-211-5p target gene FMS-like tyrosine kinase-1 (FLT-1), influencing the characteristics of CCSCs 173 (Table 1).Table 1. Functions of miRNAs in the CRC and CSC.

miRNA	Function	Reference	
Colorectal cancer	
 miR-15a	Inhibition of the BCL-2-associated anti-apoptotic pathway	55	
 miR-92a	Inhibition of the SOCS3	165	
 MiR-3065-3p	Repression of the downstream gene CRLF1	172	
Colorectal cancer stem cells	
 miR-148a	Inhibition of the expression of stem cell markers	114,163	
 miR-7-5p	Targeting KLF4 to increase radiosensitivity	160	
 miR-320d	Inhibition of the expression of c-Myc	161	
 miRNA-483-3p	Activation of the ERBB3-AKT signaling pathway	166	
 miR-103/107	Activation of the Wnt signaling pathway	167,168	
 miR - 8063	169	
 miR-451	170	
 Stem cell-associated miRNA (miR-302, miR-369, miR-200c)	Alleviating the inhibition of MRP8 (ABCC11)	171	
 miR-211-5p	Promoting the expression of the miR-211-5p target gene FLT-1	173	

Interaction Between Tumor Microenvironment and CCSCs to Regulate Drug Resistance

Tumor microenvironment (TME) serves as a dynamic interaction hub for tumor cells, including vascular components, immune cells, and other elements. 174 As previously documented, CSCs reside in specific niches where a cocktail of cytokines and soluble factors govern their stem-like properties, fueling their self-renewal capabilities.175,176 The maintenance of CSC stemness within the TME shields these cells from immune surveillance while inducing EMT, which promotes their migratory potential and facilitates the establishment of secondary tumors. 177 Activated cancer-associated fibroblasts (CAFs) release IL-11 and TGF-β signals to modify the TME and stimulate CRC progression, consequently inducing resistance to therapeutic drugs.178,179 CAFs facilitate the transmission of exosomes to CRC cells, thereby enhancing the expression of cell stemness markers such as CD133 and CD44. This process results in an elevation in the population of CD133- and CD44-positive CSCs and the initiation of an EMT phenotype in CRC cells. Consequently, this leads to an increased propensity for metastasis and chemoresistance in CRC cells. 180 The study of the relationship between TME and CSCs, which share a similar mechanism of drug resistance, holds significant implications for guiding clinical drug use in CRC resistance.

Phenethyl isothiocyanate (PEITC) has the potential to regulate inflammatory chemokines, thereby inhibiting CSCs and hindering the progression of CRC. 181 Kim 182 and colleagues suggest that the augmentation of CSCs in myofibroblasts is facilitated by the activation of HES1 induced by IL-6 and IL-8 within the TME. CRC is constantly exposed to mechanical stimuli, primarily emanating from compression, matrix stiffness, and hydrodynamic forces. The stiffness of the matrix enhances the potential for distant metastasis in CRCs, altering CCSC characteristics. 183 Elevated YAP activation in CCSCs under stiffness promotes stemness marker expression, such as CD133, ALDH1, and Lgr5, and contributes to chemoresistance and cancer recurrence. 184 Cellular stiffness also affects CRC chemoresistance. Down-regulating CX43 in CRC cells reduces cellular stiffness, enhancing stemness and drug resistance. 185 Resveratrol counters TME-induced CCSC markers, promoting apoptosis and sensitizing CRC cells to 5-FU. 186 SMC1A plays a key role in CRC proliferation, drug resistance, immune microenvironment regulation, and bidirectional targeting switches in CSCs. 187 Innate immune signals from CSCs activate Fusobacterium nucleatum (Fn), leading to a proinflammatory secretory response that promotes a tumorigenic microenvironment while also exerting tumor suppressor effects. 188

The tumorigenesis and progression of cancers within the TME involve complex interactions between tumor cells and mesenchymal cells, leading to the emergence of CSCs, further sustaining the tumor as well as resistance to cytotoxic drugs. 189 These interactions play a significant role in the establishment of drug resistance in CRC, as they are mediated by various components of the TME that together form mechanisms that enhance drug resistance.

Conclusion

CSCs play a crucial role in tumor formation and metastasis, often leading to cancer recurrence and drug resistance. Traditional tumor therapies often lack precision, making it challenging to target specific sites within the drug-resistant process of CSCs. By identifying and targeting these sites, we can improve the efficiency of treatment and overcome resistance to chemotherapy, thus simplifying CRC treatment and enhancing the therapeutic process. CCSCs are key players in drug resistance of CRC, indicating their potential as targets for effective therapy. Elucidating their role in this process could aid in discovering tailored treatment strategies.

This paper highlights the significance of signaling pathways, TME, and miRNA in regulating drug resistance in CCSCs. These signaling pathways primarily act by relaying upstream signals to downstream effectors in the drug resistance mechanism. Regulatory factors play a pivotal role in governing these pathways, indirectly modulating CCSC drug resistance. The central concept of the paragraph is that miRNAs play crucial regulatory roles in CCSCs surface markers and signaling pathways, distinct from signaling pathways in terms of their influence on CRC drug resistance via distinct proteins and processes like gene transcription. The regulation of CCSCs often involves regulatory factors or protein complexes interacting with signaling pathways or alternative routes. These interactions indirectly impact cell stemness through miRNAs, modulating the expression of critical factors. Therefore, a comprehensive understanding of the intricate relationship between miRNAs and regulatory factors is necessary to further explore the underlying mechanism of CCSC drug resistance. The TME is more macroscopic than the aforementioned ones, regulating drug resistance not solely through its internal components, but also by leveraging its innate attributes, including matrix stiffness and the establishment of a tailored microenvironment. Hence, comprehension of the TME’s macroscopic properties and modulation of its component interactions hold key clinical relevance for mitigating drug resistance and enhancing therapeutic outcomes.

In summary, clinical CRC studies have identified relevant targets for therapeutic action. Targeted therapies have significantly boosted CRC patient survival rates, and reducing drug resistance in CSCs holds promise for expanding treatment options. The studies above outline potential targets for clinical CRC interventions. Targeted therapies have already boosted CRC patient survival rates, and reducing drug resistance in CSCs represents a promising avenue for further expanding treatment options. Nevertheless, it is important to acknowledge the heterogeneity of tumors and the ongoing reliance on animal studies in some research. These constraints should be considered when designing new clinical trials, emphasizing the necessity for additional investigation into viable and efficient treatment strategies.

Acknowledgments

We acknowledge the Department of Oncology of Jiangxi University of Chinese Medicine.

ORCID iDs

Chen Zhong https://orcid.org/0009-0007-6692-2648

Yuwei Yan https://orcid.org/0009-0005-6418-0412

Nanxin Li https://orcid.org/0009-0006-4412-0997

Author Contributions: All authors contributed to the study’s conception and design. The first manuscript draft was written by ZC, and ZC prepared Figures 1-3 and Table 1. YWY and WGJ revised the first draft, and all authors commented on previous versions of the manuscript.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Natural Science Foundation of China (Grant number 82205221, 82160925), Jiangxi Provincial Natural Science Foundation (Grant number 20224BAB206097), Jiangxi University of Traditional Chinese Medicine School-level Science and Technology Innovation Team Development Program Project (Grant number No.CXTD22011) and Jiangxi Provincial Traditional Chinese Medicine Youth Key Talents (the Fourth Tranche) Training Program (Gan Traditional Chinese Medicine Science and Education 2022 No.7).
==== Refs
References

1 Sung H Ferlay J Siegel RL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71 (3 ):209-249. doi:10.3322/caac.21660
2 Siegel RL Wagle NS Cercek A Smith RA Jemal A . Colorectal cancer statistics, 2023. CA A Cancer J Clin. 2023;73 (3 ):233-254. doi:10.3322/caac.21772
3 Duan B Zhao Y Bai J , et al. Colorectal cancer: an overview. In: Morgado-Diaz JA , ed. Gastrointestinal Cancers. Brisbane City, Australia: Exon Publications; 2022:chap 586003.
4 Vallis JWP . The role of diet and lifestyle in colorectal cancer incidence and survival. In: Morgado-Diaz JA , ed. Gastrointestinal Cancers. Brisbane City, Australia: Exon Publications; 2022. chap 585999.
5 Zhao L Fan W Luo K , et al. Construction of a TTN mutation-based prognostic model for evaluating immune microenvironment, cancer stemness, and outcomes of colorectal cancer patients. Stem Cell Int. 2023;2023 :6079957. doi:10.1155/2023/6079957
6 Saleh R Elkord E . Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65 :13-27. doi:10.1016/j.semcancer.2019.07.017 31362073
7 Zhou X An B Lin Y Ni Y Zhao X Liang X . Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies. Biomed Pharmacother. 2023;165 :115036. doi:10.1016/j.biopha.2023.115036 37354814
8 Luis G Godfroid A Nishiumi S , et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021;43 :102006. doi:10.1016/j.redox.2021.102006 34030117
9 Wang Q Shen X Chen G Du J . Drug resistance in colorectal cancer: from mechanism to clinic. Cancers. 2022;14 (12 ):2928. doi:10.3390/cancers14122928 35740594
10 Ren SN Zhang ZY Guo RJ , et al. Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. World J Gastroenterol. 2023;29 (13 ):1911-1941. doi:10.3748/wjg.v29.i13.1911 37155531
11 Jia W Huang Z Zhou L , et al. Purinergic signalling in cancer therapeutic resistance: from mechanisms to targeting strategies. Drug Resist Updates. 2023;70 :100988. doi:10.1016/j.drup.2023.100988
12 Massaro C Safadeh E Sgueglia G Stunnenberg HG Altucci L Dell'Aversana C . MicroRNA-assisted hormone cell signaling in colorectal cancer resistance. Cells. 2020;10 (1 ):39. doi:10.3390/cells10010039 33396628
13 Liu Q Li J Chang J Guo Y Wen D . The characteristics and medical applications of antler stem cells. Stem Cell Res Ther. 2023;14 (1 ):225. doi:10.1186/s13287-023-03456-8 37649124
14 Alanazi RF Alhwity BS Almahlawi RM , et al. Multilineage differentiating stress enduring (Muse) cells: a new era of stem cell-based therapy. Cells. 2023;12 (13 ):1676. doi:10.3390/cells12131676 37443710
15 Kikani CK . Metabolic “sense relay” in stem cells: a short but impactful life of PAS kinase balancing stem cell fates. Cells. 2023;12 (13 ):1751. doi:10.3390/cells12131751 37443785
16 Bahn MS Ko YG . PROM1-mediated cell signal transduction in cancer stem cells and hepatocytes. BMB Rep. 2023;56 (2 ):65-70. doi:10.5483/BMBRep.2022-0203 36617467
17 Elbadawy M Usui T Yamawaki H Sasaki K . Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers. 2018;10 (6 ):164. doi:10.3390/cancers10060164 29843359
18 Najafi M Mortezaee K Majidpoor J . Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234 :116781. doi:10.1016/j.lfs.2019.116781 31430455
19 Todaro M Alea MP Di Stefano AB , et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1 (4 ):389-402. doi:10.1016/j.stem.2007.08.001 18371377
20 Patil T Rohiwal SS Tiwari AP . Stem cells: therapeutic implications in chemotherapy and radiotherapy resistance in cancer therapy. Curr Stem Cell Res Ther. 2023;18 (6 ):750-765. doi:10.2174/1574888x17666221003125208 36200212
21 Dylla SJ Beviglia L Park IK , et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3 (6 ):e2428. doi:10.1371/journal.pone.0002428 18560594
22 Garcia-Mayea Y Mir C Masson F Paciucci R Lleonart ME . Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 2020;60 :166-180. doi:10.1016/j.semcancer.2019.07.022 31369817
23 Li Y Wang Z Ajani JA Song S . Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19 (1 ):19. doi:10.1186/s12964-020-00627-5 33588867
24 Duan B Huang C Bai J , et al. Multidrug resistance in hepatocellular carcinoma. In: Tirnitz-Parker JEE , ed. Hepatocellular Carcinoma. Brisbane, Australia: Codon Publications Copyright; 2019.
25 Shao LH Zhu L Wang M , et al. Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review). Int J Mol Med. 2023;52 (2 ):69. doi:10.3892/ijmm.2023.5272 37387415
26 Sharifi-Azad M Fathi M Cho WC , et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22 (1 ):196. doi:10.1186/s12935-022-02605-y 35590367
27 Li W Zhang H Assaraf YG , et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updates. 2016;27 :14-29. doi:10.1016/j.drup.2016.05.001
28 Mineiro R Santos C Gonçalves I Lemos M Cavaco JEB Quintela T . Regulation of ABC transporters by sex steroids may explain differences in drug resistance between sexes. J Physiol Biochem. 2023;79 (3 ):467-487. doi:10.1007/s13105-023-00957-1 36995571
29 International Transporter Consortium Giacomini KM Huang SM , et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9 (3 ):215-236. doi:10.1038/nrd3028 20190787
30 Alketbi L Al-Ali A Talaat IM Hamid Q Bajbouj K . The role of ATP-binding cassette subfamily A in colorectal cancer progression and resistance. Int J Mol Sci. 2023;24 (2 ):1344. doi:10.3390/ijms24021344 36674859
31 Gao Q Li XX Xu YM , et al. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476 :67-74. doi:10.1016/j.canlet.2020.02.007 32061752
32 Kumar D Aggarwal N Deep A , et al. An understanding of mechanism-based approaches for 1,3,4-oxadiazole scaffolds as cytotoxic agents and enzyme inhibitors. Pharmaceuticals. 2023;16 (2 ):254. doi:10.3390/ph16020254 37259401
33 Van der Jeught K Xu HC Li YJ Lu XB Ji G . Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24 (34 ):3834-3848. doi:10.3748/wjg.v24.i34.3834 30228778
34 Longley DB Johnston PG . Molecular mechanisms of drug resistance. J Pathol. 2005;205 (2 ):275-292. doi:10.1002/path.1706 15641020
35 Jha RK Levens D Kouzine F . Mechanical determinants of chromatin topology and gene expression. Nucleus. 2022;13 (1 ):94-115. doi:10.1080/19491034.2022.2038868 35220881
36 Pommier Y Nussenzweig A Takeda S Austin C . Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022;23 (6 ):407-427. doi:10.1038/s41580-022-00452-3 35228717
37 Lista MJ Jousset AC Cheng M , et al. DNA topoisomerase 1 represses HIV-1 promoter activity through its interaction with a guanine quadruplex present in the LTR sequence. Retrovirology. 2023;20 (1 ):10. doi:10.1186/s12977-023-00625-8 37254203
38 Shaojun C Li H Haixin H Guisheng L . Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018;19 (3 ):153-159. doi:10.1080/15384047.2017.1414754 29261002
39 Rodriguez SMB Kamel A Ciubotaru GV , et al. An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma. Int J Mol Sci. 2023;24 (13 ):11110. doi:10.3390/ijms241311110 37446288
40 Marin JJG Macias RIR Monte MJ , et al. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment. Cancers. 2020;12 (9 ):2605. doi:10.3390/cancers12092605 32933095
41 Van Emburgh BO Arena S Siravegna G , et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7 :13665. doi:10.1038/ncomms13665 27929064
42 Bertotti A Papp E Jones S , et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526 (7572 ):263-267. doi:10.1038/nature14969 26416732
43 Dumontet C Sikic BI . Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17 (3 ):1061-1070. doi:10.1200/jco.1999.17.3.1061 10071301
44 Jordan MA Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4 (4 ):253-265. doi:10.1038/nrc1317 15057285
45 Shelling AN Ahmed Nasef N . The role of lifestyle and dietary factors in the development of premature ovarian insufficiency. Antioxidants. 2023;12 (8 ):1601. doi:10.3390/antiox12081601 37627595
46 Adams JM Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26 (9 ):1324-1337. doi:10.1038/sj.onc.1210220 17322918
47 Ma XT Wang S Ye YJ Du RY Cui ZR Somsouk M . Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol. 2004;10 (11 ):1569-1573. doi:10.3748/wjg.v10.i11.1569 15162527
48 Xin P Xu X Deng C , et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharm. 2020;80 :106210. doi:10.1016/j.intimp.2020.106210
49 Prossomariti A Piazzi G Alquati C Ricciardiello L . Are wnt/β-catenin and PI3K/AKT/mTORC1 distinct pathways in colorectal cancer? Cell Mol Gastroenterol Hepatol. 2020;10 (3 ):491-506. doi:10.1016/j.jcmgh.2020.04.007 32334125
50 Yuan S Tao F Zhang X Zhang Y Sun X Wu D . Role of Wnt/β-catenin signaling in the chemoresistance modulation of colorectal cancer. BioMed Res Int. 2020;2020 :9390878. doi:10.1155/2020/9390878 32258160
51 Wang C Chen Q Xu H . Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance. Discov Oncol. 2021;12 (1 ):40. doi:10.1007/s12672-021-00433-6 35201496
52 Mohammed MK Shao C Wang J , et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3 (1 ):11-40. doi:10.1016/j.gendis.2015.12.004 27077077
53 Vesel M Rapp J Feller D , et al. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res. 2017;18 (1 ):52. doi:10.1186/s12931-017-0537-6 28340578
54 Guo S Chen M Li S Geng Z Jin Y Liu D . Natural products treat colorectal cancer by regulating miRNA. Pharmaceuticals. 2023;16 (8 ):1122. doi:10.3390/ph16081122 37631037
55 Wang L Zhang X Sheng L Qiu C Luo R . LINC00473 promotes the Taxol resistance via miR-15a in colorectal cancer. Biosci Rep. 2018;38 (5 ):BSR20180790. doi:10.1042/bsr20180790 30126852
56 Théry C Witwer KW Aikawa E , et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7 (1 ):1535750. doi:10.1080/20013078.2018.1535750 30637094
57 Namee NM O'Driscoll L . Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. 2018;1870 (2 ):123-136. doi:10.1016/j.bbcan.2018.07.003 30003999
58 Siveen KS Raza A Ahmed EI , et al. The role of extracellular vesicles as modulators of the tumor microenvironment, metastasis and drug resistance in colorectal cancer. Cancers. 2019;11 (6 ):746. doi:10.3390/cancers11060746 31146452
59 Angius A Scanu AM Arru C , et al. Portrait of cancer stem cells on colorectal cancer: molecular biomarkers, signaling pathways and miRNAome. Int J Mol Sci. 2021;22 (4 ):1603. doi:10.3390/ijms22041603 33562604
60 Fan B Zhang Q Wang N Wang G . LncRNAs, the molecules involved in communications with colorectal cancer stem cells. Front Oncol. 2022;12 :811374. doi:10.3389/fonc.2022.811374 35155247
61 Rassouli FB Matin MM Saeinasab M . Cancer stem cells in human digestive tract malignancies. Tumour Biol. 2016;37 (1 ):7-21. doi:10.1007/s13277-015-4155-y 26446457
62 Muenzner JK Kunze P Lindner P , et al. Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. J Cell Mol Med. 2018;22 (12 ):6238-6248. doi:10.1111/jcmm.13911 30280520
63 Lau EY Ho NP Lee TK . Cancer stem cells and their microenvironment: biology and therapeutic implications. Stem Cell Int. 2017;2017 :3714190. doi:10.1155/2017/3714190
64 Gupta PB Pastushenko I Skibinski A Blanpain C Kuperwasser C . Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2019;24 (1 ):65-78. doi:10.1016/j.stem.2018.11.011 30554963
65 Kreso A Dick JE . Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14 (3 ):275-291. doi:10.1016/j.stem.2014.02.006 24607403
66 Milanovic M Fan DNY Belenki D , et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553 (7686 ):96-100. doi:10.1038/nature25167 29258294
67 De Angelis ML Francescangeli F La Torre F Zeuner A . Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front Oncol. 2019;9 :626. doi:10.3389/fonc.2019.00626 31355143
68 Ma YS Li W Liu Y Shi Y Lin QL Fu D . Targeting colorectal cancer stem cells as an effective treatment for colorectal cancer. Technol Cancer Res Treat. 2020;19 :1533033819892261. doi:10.1177/1533033819892261 32748700
69 Che J Yu S . Ecological niches for colorectal cancer stem cell survival and thrival. Front Oncol. 2023;13 :1135364. doi:10.3389/fonc.2023.1135364 37124519
70 Visvader JE Lindeman GJ . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8 (10 ):755-768. doi:10.1038/nrc2499 18784658
71 Choi HS Kim SL Kim JH Deng HY Yun BS Lee DS . Triterpene acid (3-O-p-Coumaroyltormentic acid) isolated from aronia extracts inhibits breast cancer stem cell formation through downregulation of c-myc protein. Int J Mol Sci. 2018;19 (9 ):2528. doi:10.3390/ijms19092528 30149665
72 Desai A Yan Y Gerson SL . Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Transl Med. 2019;8 (1 ):75-81. doi:10.1002/sctm.18-0123 30328686
73 Hervieu C Christou N Battu S Mathonnet M . The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. Cancers. 2021;13 (5 ):1092. doi:10.3390/cancers13051092 33806312
74 Liu S Dontu G Wicha MS . Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005;7 (3 ):86-95. doi:10.1186/bcr1021 15987436
75 Telang N . Drug-resistant stem cells: novel approach for colon cancer therapy. Int J Mol Sci. 2022;23 (5 ):2519. doi:10.3390/ijms23052519 35269660
76 Telang NT . Stem cell models for breast and colon cancer: experimental approach for drug discovery. Int J Mol Sci. 2022;23 (16 ):9223. doi:10.3390/ijms23169223 36012489
77 Walcher L Kistenmacher AK Suo H , et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11 :1280. doi:10.3389/fimmu.2020.01280 32849491
78 Donnenberg VS Donnenberg AD . Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45 (8 ):872-877. doi:10.1177/0091270005276905 16027397
79 Nunes T Hamdan D Leboeuf C , et al. Targeting cancer stem cells to overcome chemoresistance. Int J Mol Sci. 2018;19 (12 ):4036. doi:10.3390/ijms19124036 30551640
80 Du B Shim JS . Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21 (7 ):965. doi:10.3390/molecules21070965 27455225
81 Lee SY Jeong EK Ju MK , et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16 (1 ):10. doi:10.1186/s12943-016-0577-4 28137309
82 Morrison R Schleicher SM Sun Y , et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. JAMA Oncol. 2011;2011 :941876. doi:10.1155/2011/941876
83 Safa AR . Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. Cancer Drug Resist. 2022;5 (4 ):850-872. doi:10.20517/cdr.2022.20 36627897
84 Khaledian B Thibes L Shimono Y . Adipocyte regulation of cancer stem cells. Cancer Sci. 2023;114 :4134-4144. doi:10.1111/cas.15940 37622414
85 Lathia JD Heddleston JM Venere M Rich JN . Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 2011;8 (5 ):482-485. doi:10.1016/j.stem.2011.04.013 21549324
86 Heddleston JM Li Z McLendon RE Hjelmeland AB Rich JN . The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8 (20 ):3274-3284. doi:10.4161/cc.8.20.9701 19770585
87 O'Reilly D Johnson P Buchanan PJ . Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer. Steroids. 2019;152 :108497. doi:10.1016/j.steroids.2019.108497 31521707
88 Gerson SL Reese J Kenyon J . DNA repair in stem cell maintenance and conversion to cancer stem cells. Ernst Schering Found Symp Proc 2006;5 :231-244. doi:10.1007/2789_2007_053
89 Skvortsov S Debbage P Lukas P Skvortsova I . Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol. 2015;31 :36-42. doi:10.1016/j.semcancer.2014.06.002 24954010
90 Janta S Pranweerapaiboon K Vivithanaporn P , et al. Holothurin a inhibits RUNX1-enhanced EMT in metastasis prostate cancer via the Akt/JNK and P38 MAPK signaling pathway. Mar Drugs. 2023;21 (6 ):345. doi:10.3390/md21060345 37367670
91 Polyak K Weinberg RA . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9 (4 ):265-273. doi:10.1038/nrc2620 19262571
92 Ghosh P Fontanella RA Scisciola L , et al. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists. Theranostics. 2023;13 (14 ):4872-4884. doi:10.7150/thno.86831 37771773
93 Nguyen VN Li H . Recent development of lysosome-targeted organic fluorescent probes for reactive oxygen species. Molecules. 2023;28 (18 ):6650. doi:10.3390/molecules28186650 37764426
94 Liou GY Storz P . Reactive oxygen species in cancer. Free Radic Res. 2010;44 (5 ):479-496. doi:10.3109/10715761003667554 20370557
95 Wang H Zhang Z Ruan S , et al. Regulation of iron metabolism and ferroptosis in cancer stem cells. Front Oncol. 2023;13 :1251561. doi:10.3389/fonc.2023.1251561 37736551
96 Garimella SV Gampa SC Chaturvedi P . Mitochondria in cancer stem cells: from an innocent bystander to a central player in therapy resistance. Stem Cells Cloning. 2023;16 :19-41. doi:10.2147/sccaa.S417842 37641714
97 Zanoni M Bravaccini S Fabbri F Arienti C . Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance. Front Med. 2022;9 :795762. doi:10.3389/fmed.2022.795762
98 Clark DW Palle K . Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med. 2016;4 (24 ):518. doi:10.21037/atm.2016.11.82 28149880
99 Dalerba P Dylla SJ Park IK , et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104 (24 ):10158-10163. doi:10.1073/pnas.0703478104 17548814
100 Xuan SH Hua ML Xiang Z , et al. Roles of cancer stem cells in gastrointestinal cancers. World J Stem Cell. 2023;15 (4 ):209-220. doi:10.4252/wjsc.v15.i4.209
101 Zhou Y Xia L Wang H , et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9 (70 ):33403-33415. doi:10.18632/oncotarget.23607 30279970
102 Gao W Chen L Ma Z , et al. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology. 2013;145 (3 ):636-646. doi:10.1053/j.gastro.2013.05.049 23747337
103 Hwang GR Yuen JG Ju J . Roles of microRNAs in gastrointestinal cancer stem cell resistance and therapeutic development. Int J Mol Sci. 2021;22 (4 ):1624. doi:10.3390/ijms22041624 33562727
104 Novoa Díaz MB Carriere P Gentili C . How the interplay among the tumor microenvironment and the gut microbiota influences the stemness of colorectal cancer cells. World J Stem Cell. 2023;15 (5 ):281-301. doi:10.4252/wjsc.v15.i5.281
105 Hardin H Zhang R Helein H Buehler D Guo Z Lloyd RV . The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors. Lab Invest. 2017;97 (10 ):1142-1151. doi:10.1038/labinvest.2017.41 28394318
106 He L Zhu H Zhou S , et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp Mol Med. 2018;50 (8 ):101-112. doi:10.1038/s12276-018-0128-8 30111797
107 Ordaz-Ramos A Tellez-Jimenez O Vazquez-Santillan K . Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications. Front Cell Dev Biol. 2023;11 :1221175. doi:10.3389/fcell.2023.1221175 37492224
108 Kenneth MJ Shishir TA Haque FKM . In silico analysis reveals mir-98-5p as a potential inhibitor of tumor cell proliferation and metastasis in colorectal cancer by targeting the fzd3 receptor of the Wnt signaling pathway. J Genet Eng Biotechnol. 2023;21 (1 ):79. doi:10.1186/s43141-023-00532-7 37466730
109 Borlongan MC Wang H . Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics. Front Cell Dev Biol. 2023;11 :1125174. doi:10.3389/fcell.2023.1125174 37305676
110 Hoffmeyer K Raggioli A Rudloff S , et al. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science. 2012;336 (6088 ):1549-1554. doi:10.1126/science.1218370 22723415
111 Clevers H Loh KM Nusse R . Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346 (6205 ):1248012. doi:10.1126/science.1248012 25278615
112 Schulenburg A Cech P Herbacek I , et al. CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol. 2007;213 (2 ):152-160. doi:10.1002/path.2220 17708598
113 Katoh M Katoh M . WNT signaling and cancer stemness. Essays Biochem. 2022;66 (4 ):319-331. doi:10.1042/ebc20220016 35837811
114 Silva VR Santos LS Dias RB Quadros CA Bezerra DP . Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells. Cancer Commun. 2021;41 (12 ):1275-1313. doi:10.1002/cac2.12235
115 Cheng X Xu X Chen D Zhao F Wang W . Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. Biomed Pharmacother. 2019;110 :473-481. doi:10.1016/j.biopha.2018.11.082 30530050
116 Morin PJ Sparks AB Korinek V , et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275 (5307 ):1787-1790. doi:10.1126/science.275.5307.1787 9065402
117 Markowitz SD Bertagnolli MM . Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361 (25 ):2449-2460. doi:10.1056/NEJMra0804588 20018966
118 Zhang L Shay JW . Multiple roles of APC and its therapeutic implications in colorectal cancer. J Natl Cancer Inst. 2017;109 (8 ). doi:10.1093/jnci/djw332
119 Zhan T Ambrosi G Wandmacher AM , et al. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer. Nat Commun. 2019;10 (1 ):2197. doi:10.1038/s41467-019-09898-0 31097693
120 Liu YS Hsu HC Tseng KC Chen HC Chen SJ . Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomed Pharmacother. 2013;67 (8 ):791-799. doi:10.1016/j.biopha.2013.08.001 24138824
121 Zhu GX Gao D Shao ZZ Chen L Ding WJ Yu QF . Wnt/β‑catenin signaling: causes and treatment targets of drug resistance in colorectal cancer (Review). Mol Med Rep. 2021;23 (2 ):105. doi:10.3892/mmr.2020.11744 33300082
122 Wang T Ning K Lu TX Hua D . Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer. Oncol Rep. 2017;37 (2 ):1059-1065. doi:10.3892/or.2016.5322 28000878
123 He K Gan WJ . Wnt/β-Catenin signaling pathway in the development and progression of colorectal cancer. Cancer Manag Res. 2023;15 :435-448. doi:10.2147/cmar.S411168 37250384
124 Kahn M . Symmetric division versus asymmetric division: a tale of two coactivators. Future Med Chem. 2011;3 (14 ):1745-1763. doi:10.4155/fmc.11.126 22004083
125 Park S-Y Kim J-Y Jang G-B , et al. Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells. Theranostics. 2021;11 (18 ):8755-8770. doi:10.7150/thno.63446 34522210
126 Liu X Su K Sun X , et al. Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway. J Exp Clin Cancer Res. 2021;40 (1 ):132. doi:10.1186/s13046-021-01934-6 33858476
127 Si Y Li L Zhang W Liu Q Liu B . GANT61 exerts anticancer cell and anticancer stem cell capacity in colorectal cancer by blocking the Wnt/β-catenin and Notch signalling pathways. Oncol Rep. 2022;48 (4 ):182. doi:10.3892/or.2022.8397 36069229
128 Chen Y Yang Z He X , et al. Proanthocyanidins inhibited colorectal cancer stem cell characteristics through Wnt/β-catenin signaling. Environ Toxicol. 2023;38 (12 ):2894-2903. doi:10.1002/tox.23924 37551626
129 Yang L Shi P Zhao G , et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Targeted Ther. 2020;5 (1 ):8. doi:10.1038/s41392-020-0110-5
130 Ebrahimi N Afshinpour M Fakhr SS , et al. Cancer stem cells in colorectal cancer: signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol Hematol. 2023;182 :103920. doi:10.1016/j.critrevonc.2023.103920 36702423
131 Shaik JP Alanazi IO Pathan AAK , et al. Frequent activation of notch signaling pathway in colorectal cancers and its implication in patient survival outcome. JAMA Oncol. 2020;2020 :6768942-6768948. doi:10.1155/2020/6768942
132 Pan T Xu J Zhu Y . Self-renewal molecular mechanisms of colorectal cancer stem cells. Int J Mol Med. 2017;39 (1 ):9-20. doi:10.3892/ijmm.2016.2815 27909729
133 Gupta R Bhatt LK Johnston TP Prabhavalkar KS . Colon cancer stem cells: potential target for the treatment of colorectal cancer. Cancer Biol Ther. 2019;20 (8 ):1068-1082. doi:10.1080/15384047.2019.1599660 31050577
134 Huang B Yang H Cheng X , et al. tRF/miR-1280 suppresses stem cell-like cells and metastasis in colorectal cancer. Cancer Res. 2017;77 (12 ):3194-3206. doi:10.1158/0008-5472.Can-16-3146 28446464
135 Jin L Vu T Yuan G Datta PK . STRAP promotes stemness of human colorectal cancer via epigenetic regulation of the NOTCH pathway. Cancer Res. 2017;77 (20 ):5464-5478. doi:10.1158/0008-5472.Can-17-0286 28827371
136 Jo MK Moon CM Kim EJ , et al. Suppressive effect of α-mangostin for cancer stem cells in colorectal cancer via the Notch pathway. BMC Cancer. 2022;22 (1 ):341. doi:10.1186/s12885-022-09414-6 35351071
137 Chandra Boinpelly V Verma RK Srivastav S Srivastava RK Shankar S . α-Mangostin-encapsulated PLGA nanoparticles inhibit colorectal cancer growth by inhibiting Notch pathway. J Cell Mol Med. 2020;24 (19 ):11343-11354. doi:10.1111/jcmm.15731 32830433
138 Zhang F Sun H Zhang S Yang X Zhang G Su T . Overexpression of PER3 inhibits self-renewal capability and chemoresistance of colorectal cancer stem-like cells via inhibition of notch and β-catenin signaling. Oncol Res. 2017;25 (5 ):709-719. doi:10.3727/096504016x14772331883976 27983919
139 Neradugomma NK Subramaniam D Tawfik OW , et al. Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis. 2014;35 (4 ):795-806. doi:10.1093/carcin/bgt379 24265293
140 Qiu L Yang X Wu J Huang C Miao Y Fu Z . HIST2H2BF potentiates the propagation of cancer stem cells via notch signaling to promote malignancy and liver metastasis in colorectal carcinoma. Front Oncol. 2021;11 :677646. doi:10.3389/fonc.2021.677646 34476209
141 Kim H Yu Y Choi S , et al. Evodiamine eliminates colon cancer stem cells via suppressing notch and Wnt signaling. Molecules. 2019;24 (24 ):4520. doi:10.3390/molecules24244520 31835579
142 Skoda AM Simovic D Karin V Kardum V Vranic S Serman L . The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J Basic Med Sci. 2018;18 (1 ):8-20. doi:10.17305/bjbms.2018.2756 29274272
143 Peacock CD Wang Q Gesell GS , et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. 2007;104 (10 ):4048-4053. doi:10.1073/pnas.0611682104 17360475
144 Katoh Y Katoh M . Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med. 2006;18 (6 ):1019-1023.17089004
145 Regan JL Schumacher D Staudte S , et al. Non-canonical hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells. Cell Rep. 2017;21 (10 ):2813-2828. doi:10.1016/j.celrep.2017.11.025 29212028
146 Varnat F Duquet A Malerba M , et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med. 2009;1 (6-7 ):338-351. doi:10.1002/emmm.200900039 20049737
147 Wei Y Li Y Chen Y , et al. ALDH1: a potential therapeutic target for cancer stem cells in solid tumors. Front Oncol. 2022;12 :1026278. doi:10.3389/fonc.2022.1026278 36387165
148 Yang Y Nguyen TT Pereira I Hur JS Kim H . Lichen secondary metabolite Physciosporin decreases the stemness potential of colorectal cancer cells. Biomolecules. 2019;9 (12 ):797. doi:10.3390/biom9120797 31795147
149 Batsaikhan BE Yoshikawa K Kurita N , et al. Cyclopamine decreased the expression of Sonic Hedgehog and its downstream genes in colon cancer stem cells. Anticancer Res. 2014;34 (11 ):6339-6344.25368233
150 Zhou Y Qiu S Kim JT , et al. Garcinone C suppresses tumorsphere formation and invasiveness by hedgehog/Gli1 signaling in colorectal cancer stem-like cells. J Agric Food Chem. 2022;70 (26 ):7941-7952. doi:10.1021/acs.jafc.2c01891 35749593
151 Kim BR Na YJ Kim JL , et al. RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. Cell Death Differ. 2020;27 (2 ):676-694. doi:10.1038/s41418-019-0379-5 31278361
152 Choi JK Kwak IS Yoon SB Cho H Moon BS . A small molecule promoting neural differentiation suppresses cancer stem cells in colorectal cancer. Biomedicines. 2022;10 (4 ):859. doi:10.3390/biomedicines10040859 35453609
153 Park JH Kim YH Shim S , et al. Radiation-activated PI3K/AKT pathway promotes the induction of cancer stem-like cells via the upregulation of SOX2 in colorectal cancer. Cells. 2021;10 (1 ):135. doi:10.3390/cells10010135 33445526
154 Zalewski A Snook AE Waldman SA . Stem cells as therapeutic targets in colorectal cancer. Méd. 2021;18 (2 ):171-183. doi:10.2217/pme-2020-0099
155 Park SY Lee CJ Choi JH , et al. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res. 2019;38 (1 ):399. doi:10.1186/s13046-019-1405-7 31511084
156 Stark VA Facey COB Viswanathan V Boman BM . The role of miRNAs, miRNA clusters, and isomiRs in development of cancer stem cell populations in colorectal cancer. Int J Mol Sci. 2021;22 (3 ):1424. doi:10.3390/ijms22031424 33572600
157 Jia Q Liao X Xu B Li Y Liang L . MiR-128-1-5p inhibits cell proliferation and induces cell apoptosis via targeting PRKCQ in colorectal cancer. Cancer Biol Ther. 2023;24 (1 ):2226421. doi:10.1080/15384047.2023.2226421 37358216
158 Chao H-M Wang T-W Chern E Hsu S-H . Regulatory RNAs, microRNA, long-non coding RNA and circular RNA roles in colorectal cancer stem cells. World J Gastrointest Oncol. 2022;14 (4 ):748-764. doi:10.4251/wjgo.v14.i4.748 35582099
159 Stark VA Facey COB Opdenaker L Fields JZ Boman BM . Differential miRNA expression contributes to emergence of multiple cancer stem cell subpopulations in human colorectal cancer. bioRxiv 2023;13 (2 ):582. doi:10.1101/2023.02.06.527341
160 Shang Y Zhu Z Zhang Y , et al. MiR-7-5p/KLF4 signaling inhibits stemness and radioresistance in colorectal cancer. Cell Death Dis. 2023;9 (1 ):42. doi:10.1038/s41420-023-01339-8
161 Liu C Wang JL Wu DZ Yuan YW Xin L . Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis. Mol Cell Biochem. 2022;477 (7 ):2001-2013. doi:10.1007/s11010-022-04416-1 35394639
162 Li Y Wang W Wu M , et al. LncRNA LINC01315 silencing modulates cancer stem cell properties and epithelial-to-mesenchymal transition in colorectal cancer via miR-484/DLK1 axis. Cell Cycle. 2022;21 (8 ):851-873. doi:10.1080/15384101.2022.2033415 35156543
163 Shi L Xi J Xu X Peng B Zhang B . MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed Pharmacother. 2019;109 :902-909. doi:10.1016/j.biopha.2018.10.080 30551544
164 Bansard L Bouvet O Moutin E , et al. Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy. Stem Cell Rep. 2022;17 (4 ):835-848. doi:10.1016/j.stemcr.2022.02.005
165 Li L Zhang J Peng H , et al. Knockdown of miR-92a suppresses the stemness of colorectal cancer cells via mediating SOCS3. Bioengineered. 2022;13 (3 ):5613-5624. doi:10.1080/21655979.2021.2022267 35184640
166 Candiello E Reato G Verginelli F , et al. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. Mol Oncol. 2023;17 (7 ):1280-1301. doi:10.1002/1878-0261.13408 36862005
167 Wang LQ Yu P Li B , et al. miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. Mol Oncol. 2018;12 (11 ):1949-1964. doi:10.1002/1878-0261.12376 30171794
168 Yeoh Y Low TY Abu N Lee PY . Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ. 2021;9 :e12338. doi:10.7717/peerj.12338 34733591
169 Chen ZQ Yuan T Jiang H , et al. MicroRNA-8063 targets heterogeneous nuclear ribonucleoprotein AB to inhibit the self-renewal of colorectal cancer stem cells via the Wnt/β-catenin pathway. Oncol Rep. 2021;46 (4 ):219. doi:10.3892/or.2021.8170 34396427
170 Zhang Y Wang J . MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol Chem. 2017;398 (8 ):929-938. doi:10.1515/hsz-2016-0308 28095367
171 Xie T Huang M Wang Y Wang L Chen C Chu X . MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer. Cell Physiol Biochem. 2016;40 (1-2 ):62-76. doi:10.1159/000452525 27842308
172 Li Y Xun J Wang B , et al. miR-3065-3p promotes stemness and metastasis by targeting CRLF1 in colorectal cancer. J Transl Med. 2021;19 (1 ):429. doi:10.1186/s12967-021-03102-y 34656128
173 Huang Y Wang L Liu D . HOTAIR regulates colorectal cancer stem cell properties and promotes tumorigenicity by sponging miR-211-5p and modulating FLT-1. Cell Cycle. 2021;20 (19 ):1999-2009. doi:10.1080/15384101.2021.1962636 34470574
174 Quail DF Joyce JA . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19 (11 ):1423-1437. doi:10.1038/nm.3394 24202395
175 Plaks V Kong N Werb Z . The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16 (3 ):225-238. doi:10.1016/j.stem.2015.02.015 25748930
176 Conciatori F Bazzichetto C Falcone I , et al. Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement. Cancer Drug Resist. 2019;2 (4 ):968-979. doi:10.20517/cdr.2019.56 35582268
177 Zhao Y Dong Q Li J , et al. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. Semin Cancer Biol. 2018;53 :139-155. doi:10.1016/j.semcancer.2018.08.002 30081228
178 Lv MY Cai D Li CH , et al. Senescence-based colorectal cancer subtyping reveals distinct molecular characteristics and therapeutic strategies. MedComm. 2023;4 (4 ):333. doi:10.1002/mco2.333
179 Huang K Zhang X Hao Y , et al. Hypoxia tumor microenvironment activates GLI2 through HIF-1α and TGF-β2 to promote chemotherapy resistance of colorectal cancer. Comput Math Methods Med. 2022;2022 :2032895. doi:10.1155/2022/2032895 35186110
180 Hu JL Wang W Lan XL , et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18 (1 ):91. doi:10.1186/s12943-019-1019-x 31064356
181 Shin JM Lim E Cho YS Nho CW . Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model. Phytomedicine. 2021;84 :153493. doi:10.1016/j.phymed.2021.153493 33626429
182 Kim B Seo Y Kwon JH , et al. IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. Mol Carcinog. 2021;60 (3 ):188-200. doi:10.1002/mc.23283 33544929
183 Liu C Pei H Tan F . Matrix stiffness and colorectal cancer. OncoTargets Ther. 2020;13 :2747-2755. doi:10.2147/ott.S231010
184 Safaei S Sajed R Shariftabrizi A , et al. Tumor matrix stiffness provides fertile soil for cancer stem cells. Cancer Cell Int. 2023;23 (1 ):143. doi:10.1186/s12935-023-02992-w 37468874
185 Han Y Wang H Chen H , et al. CX43 down-regulation promotes cell aggressiveness and 5-fluorouracil-resistance by attenuating cell stiffness in colorectal carcinoma. Cancer Biol Ther. 2023;24 (1 ):2221879. doi:10.1080/15384047.2023.2221879 37342072
186 Brockmueller A Girisa S Kunnumakkara AB Shakibaei M . Resveratrol modulates chemosensitisation to 5-FU via β1-integrin/HIF-1α Axis in CRC tumor microenvironment. Int J Mol Sci. 2023;24 (5 ):4988. doi:10.3390/ijms24054988 36902421
187 Li J Zhou Q Liu L He J . Effects of SMC1A on immune microenvironment and cancer stem cells in colon adenocarcinoma. Cancer Med. 2023;12 (11 ):12881-12895. doi:10.1002/cam4.5891 37096492
188 Cavallucci V Palucci I Fidaleo M , et al. Proinflammatory and cancer-promoting pathobiont Fusobacterium nucleatum directly targets colorectal cancer stem cells. Biomolecules. 2022;12 (9 ):1256. doi:10.3390/biom12091256 36139097
189 Wei Z Wang Z Chai Q , et al. Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling-mediated Sox2 and PD-L1 expression. Exp Ther Med. 2023;25 (2 ):86. doi:10.3892/etm.2023.11785 36741914
